Zero Candida Technologies: A Year of Milestones and Challenges

In the rapidly evolving world of FemTech, Zero Candida Technologies, Inc. (TSXV: ZCT) (OTCQB: ZCTFF) (FSE: 9L2) has emerged as a beacon of innovation, revolutionizing women's health with its groundbreaking device for treating Candidiasis. The company's recent financial results and business highlights for the year ended December 31, 2024, paint a picture of a company on the cusp of significant breakthroughs, but also one navigating the complexities of a development-stage enterprise.

The year 2024 was transformative for Zero Candida. The company achieved key pre-clinical milestones, completed its public listing, and is now well-positioned to accelerate its development plans. Eli Ben Haroosh, Zero Candida's CEO, highlighted the company's progress, stating, "2024 was a transformative year for Zero Candida. We achieved key pre-clinical milestones, completed our public listing, and are now well-positioned to accelerate our development plans. Looking ahead, we are focused on advancing towards clinical trials and bringing our groundbreaking device for Candidiasis to market, addressing a critical unmet need in women's health."

The financial results for 2024 reflect the company's continued investment in the development of its Candidiasis treatment technology. Research and development expenses decreased to CAD 1,276 thousand from CAD 1,868 thousand in 2023, while general and administrative expenses increased to CAD 965 thousand from CAD 649 thousand in 2023. The operating loss for 2024 was CAD 6,241 thousand, which included CAD 4,000 thousand in issuance costs related to the reverse acquisition, compared to an operating loss of CAD 2,517 thousand in 2023. The net loss for 2024 was CAD 6,283 thousand, compared to CAD 2,513 thousand in 2023.

Despite the financial challenges, Zero Candida's cash position remains strong. As of December 31, 2024, cash and cash equivalents and bank deposits totaled CAD 3,052 thousand, an increase from CAD 1,639 thousand as of December 31, 2023. Total assets were CAD 3,214 thousand, and shareholders' equity was CAD 2,341 thousand, compared to CAD 1,693 thousand, and CAD 1,301 thousand, respectively, as of December 31, 2023.

The company's strategic moves in 2024, including its public listings on the TSX Venture Exchange, Frankfurt Stock Exchange, and OTCQB Venture Market, have expanded its access to capital and increased its visibility and credibility in the global market. These listings have also diversified its investor base, providing access to different investor pools and reducing reliance on a single market or investor group.

However, the company's journey is not without its challenges. The resignation of Ms. Orit Berger from the Board of Directors for personal reasons, effective immediately, adds an element of uncertainty. The company will need to navigate this transition while continuing to focus on its development plans and clinical trials.

In conclusion, Zero Candida Technologies' 2024 financial results and business highlights reflect a company on the brink of significant breakthroughs in women's health. While the financial challenges are evident, the company's strong cash position, strategic listings, and innovative technology position it for long-term success. As the company advances towards clinical trials and brings its groundbreaking device for Candidiasis to market, it will be crucial to monitor its progress and navigate the complexities of a development-stage enterprise.